Latest Capital Raising News

Ballard Mining has raised $61 million through a well-supported placement to fund an aggressive drilling program and early development works at its Mt Ida Gold Project, positioning the company for a Final Investment Decision.

Nyrada Inc. has secured ethics approval to launch a Phase IIa clinical trial for its heart attack drug Xolatryp®, with patient recruitment set for March 2026. The company maintains a solid cash position of AU$7.12 million as it expands its research into oncology.

Bounty Oil & Gas has announced a significant board renewal, including the appointment of Kane Marshall as Chairman and the retirement of long-serving CEO Philip Kelso. These leadership changes mark a new chapter as the company pursues growth in its Australian oil and gas assets.

American Tungsten & Antimony Ltd is progressing its Nasdaq listing plans with a confidential SEC filing expected in March 2026 and has appointed Deutsche Bank as ADR depositary alongside a new CFO to support growth.

Venus Metals Corporation progresses its Sandstone Bellchambers gold project with a new mining lease and exploration targets, while extending its Bridgetown JV farm-in and navigating an unsolicited takeover offer.

Xenora Minerals has resumed on-ground exploration at its Dudley Lithium Project in South Australia following a detailed geochemical review, supported by a recent $2.1 million capital raise. The company ends the quarter with a strong cash position, positioning itself for further growth in the critical minerals sector.

Pivotal Metals has raised $5.4 million, including $1.1 million in non-dilutive funding, to ramp up exploration across its Québec copper, gold, PGM, and nickel projects, unveiling multiple high-priority drill targets and advancing resource optimisation at Horden Lake.

West Coast Silver has completed a significant phase of drilling at its Elizabeth Hill Silver Project, revealing visible native silver in multiple holes and securing $3.2 million in fresh capital to advance exploration and processing studies.

Invex Therapeutics reports promising new data from its collaboration with Tessara Therapeutics on Exenatide’s potential in Alzheimer’s disease, alongside significant board changes and a solid cash position at quarter’s end.

Anteris Technologies Global Corp. has launched a $230 million equity offering alongside an $84 million private placement with Medtronic’s subsidiary, aiming to accelerate clinical trials and scale manufacturing of its innovative DurAVR Transcatheter Heart Valve.

Critica Limited has successfully closed the second tranche of its $8 million placement, issuing over 92 million shares and options to accelerate development at its Jupiter Rare Earth Project.

Marvel Gold Limited has initiated a comprehensive drone-borne magnetic survey over its Hanang Gold Project in Tanzania and entered a binding agreement to divest its Yanfolila Gold Project in Mali, signalling a strategic shift in its asset portfolio.